

REPORT TO THE LEGISLATURE
Pursuant to P.A. 119 of 2023
Article 2, Section 604
Hepatitis C Treatment Report

Sec. 604. (1) Funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment, By February 15, the department shall issue a report for the prior fiscal year showing the total amount spent on specialty medication for the treatment of Hepatitis C, the number of prisoners who were treated, the amount of any rebates that were received from the purchase of specialty medication, and what outstanding rebates are expected to be received.

(2) The report must include the Hepatitis C status of all incoming prisoners and the number of prisoners who are reinfected while incarcerated and require retreatment for Hepatitis C. The report must also include the number of those treated and released and then retreated upon reincarceration.

The total average monthly prisoner census for FY2023 was 32,641.

	# of Prisoners that started treatment during QTR	Total # of prisoners in Treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate rec'd
1st QTR FY 2023	118	210	125	\$ 1,940,835	\$ (57,403)
2nd QTR FY 2023	85	170	101	\$ 1,393,333	\$ (38,316)
3rd QTR FY 2023	52	121	80	\$ 991,174	\$ (57,784)
4th QTR FY 2023	192	232	65	\$ 2,761,725	\$ (96,008)

Fibrosis Stage of Incoming, Treated Prisoners					
	Stage 0	Stage 1	Stage 2	Stage 3	Stage 4
Number of Prisoners	96	193	133	78	39